UBS AG set a $16.00 price target on Horizon Pharma PLC (NASDAQ:HZNP) in a report published on Tuesday morning, www.tipranks.com reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
HZNP has been the subject of a number of other research reports. Cantor Fitzgerald started coverage on Horizon Pharma PLC in a research report on Friday, June 16th. They set an overweight rating and a $13.00 target price for the company. ValuEngine downgraded Horizon Pharma PLC from a buy rating to a hold rating in a research report on Friday, June 2nd. Piper Jaffray Companies set a $17.00 target price on Horizon Pharma PLC and gave the stock a buy rating in a research report on Tuesday, July 25th. BMO Capital Markets restated a buy rating and set a $17.00 target price (down previously from $24.00) on shares of Horizon Pharma PLC in a research report on Tuesday, May 9th. Finally, Jefferies Group LLC set a $26.00 target price on Horizon Pharma PLC and gave the stock a buy rating in a research report on Wednesday, April 12th. Five equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus price target of $19.46.
Horizon Pharma PLC (NASDAQ:HZNP) opened at 12.08 on Tuesday. The stock’s 50 day moving average price is $12.44 and its 200-day moving average price is $13.66. Horizon Pharma PLC has a one year low of $9.45 and a one year high of $23.44. The firm’s market capitalization is $1.97 billion.
Horizon Pharma PLC (NASDAQ:HZNP) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.29. The company had revenue of $289.51 million during the quarter, compared to the consensus estimate of $237.01 million. Horizon Pharma PLC had a positive return on equity of 22.85% and a negative net margin of 42.40%. The firm’s quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.56 earnings per share. On average, equities research analysts anticipate that Horizon Pharma PLC will post $1.07 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://stocknewstimes.com/2017/08/12/ubs-ag-reiterates-16-00-price-target-for-horizon-pharma-plc-hznp.html.
Horizon Pharma PLC announced that its board has approved a share repurchase plan on Monday, May 8th that authorizes the company to repurchase 1,000% of shares. This repurchase authorization authorizes the biopharmaceutical company to buy shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its stock is undervalued.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its position in Horizon Pharma PLC by 68,479.5% in the first quarter. BlackRock Inc. now owns 13,261,212 shares of the biopharmaceutical company’s stock worth $196,001,000 after buying an additional 13,241,875 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Horizon Pharma PLC by 119.4% in the second quarter. Dimensional Fund Advisors LP now owns 6,265,608 shares of the biopharmaceutical company’s stock worth $74,373,000 after buying an additional 3,409,411 shares during the last quarter. William Blair Investment Management LLC acquired a new position in Horizon Pharma PLC during the second quarter worth about $23,557,000. Highbridge Capital Management LLC boosted its position in Horizon Pharma PLC by 128.2% in the first quarter. Highbridge Capital Management LLC now owns 1,545,169 shares of the biopharmaceutical company’s stock worth $22,837,000 after buying an additional 867,927 shares during the last quarter. Finally, Janus Capital Management LLC boosted its position in Horizon Pharma PLC by 19.4% in the first quarter. Janus Capital Management LLC now owns 4,409,717 shares of the biopharmaceutical company’s stock worth $65,173,000 after buying an additional 717,643 shares during the last quarter. 82.95% of the stock is owned by hedge funds and other institutional investors.
About Horizon Pharma PLC
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.